首页> 外国专利> METHOD FOR PREDICTION OF THE EFFECTIVENESS OF THE AGENT FOR INCREASING THE HIGH-DIFFERENTIATED CELLS IN MAMMARY ADENOCARCINOMA AND THE COMPOSITION FOR ITS IMPLEMENTATION

METHOD FOR PREDICTION OF THE EFFECTIVENESS OF THE AGENT FOR INCREASING THE HIGH-DIFFERENTIATED CELLS IN MAMMARY ADENOCARCINOMA AND THE COMPOSITION FOR ITS IMPLEMENTATION

机译:预测乳腺腺瘤中高分化细胞的增效剂的功效及其实现方法的组成

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to predict the effectiveness of the agent for increasing the relative content of high-differentiated cells in adenocarcinoma of the patient's breast with invasive protocol cancer. Said agent for increasing the high-grade cell content is a composition consisting of phytohemagglutinin P, phytohemagglutinin M, concanavalin A, lipopolysaccharide from Escherichia coli, taken in ratio (pts.wt) 1:1:2:1 respectively (hereinafter – Composition). Concentration of cytokines IL-6, TNF-α and G-CSF in a supernatant of the patient's blood sample incubated with the Composition and without it. Composition effect index is then calculated (CEITC) on total production of cytokines IL-6, TNF-α and G-CSF by immunocompetent blood cells by formula: CEITC=(AIL-6+ATNF-α+AG-CSF):(BIL-6+BTNF-α+BG-CSF), where AIL-6, ATNF-α, AG-CSF – concentration (pg/ml) of IL-6, TNF-α and G-CSF in the patient's blood sample supernatant incubated with the Composition, and BIL-6, BTNF-α, BG-CSF – concentration of IL-6, TNF-α and G-CSF in a supernatant of a patient's blood sample incubated without Composition. At value of CEITC, equal to or greater than 700, an increase in the relative content of high-differentiated cells in the adenocarcinoma of the patient's breast by the Composition is predicted.;EFFECT: use of the given method enables selecting the patients in whom using the Composition it is possible to increase relative content of high-differentiated cells in the tumor and reduce its malignancy; composition has the properties to stimulate differentiation of tumor cells in a number of patients and to stimulate the development of immunocompetent cells of the given group of patients.;1 cl, 3 ex, 2 tbl, 3 dwg
机译:技术领域本发明涉及医学,即肿瘤学,并且可以用于预测该试剂用于增加患有浸润性协议癌的患者的乳房腺癌中高分化细胞的相对含量的试剂的有效性。所述用于增加高级细胞含量的试剂是由植物血凝素P,植物血凝素M,伴刀豆球蛋白A,来自大肠杆菌的脂多糖组成的组合物,其比例分别为(pts.wt)1:1:2:1(以下称“组合物”) 。与组合物一起温育和不与组合物一起温育的患者血液样品上清液中细胞因子IL-6,TNF-α和G-CSF的浓度。然后计算有免疫能力的血细胞对细胞因子IL-6,TNF-α和G-CSF总产生的组成效应指数(CEI TC ),计算公式为:CEI TC = (A IL-6 + A TNF-α + A G-CSF ):( B IL-6 + B TNF-α + B G-CSF ),其中A IL-6 ,A TNF-α ,A G-CSF –用该组合物孵育的患者血液样本上清液中IL-6,TNF-α和G-CSF的浓度(pg / ml) ,B TNF-α,B G-CSF –患者血液样本上清液中IL-6,TNF-α和G-CSF的浓度不用组合物孵育。当CEI TC 的值等于或大于700时,预计该组合物会使患者乳房腺癌中高分化细胞的相对含量增加。给定的方法能够选择使用该组合物的患者,可以增加肿瘤中高分化细胞的相对含量并降低其恶性程度;该组合物具有刺激许多患者的肿瘤细胞分化和刺激给定患者组的免疫能力细胞发育的特性。1cl,3 ex,2 tbl,3 dwg

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号